Friday, March 3, 2023 Daily Archives

Samsung Biologics bags another Big Pharma with $185m Pfizer deal

by

Pfizer becomes the seventh top 10 pharma firm to ink a deal with Korean CDMO Samsung Biologics. According to a regulatory filing, contract development and manufacturing organization (CDMO) Samsung Biologics will supply biologics services for pharma giant Pfizer. The contract is worth KRW 241 billion ($185 million) and is valid from February 2023 until the end of 2029. Further details have not been disclosed, but the contract is not an anomaly for the Korean CDMO, which has been inking manufacturing…

March 3, 2023

Seagen on rumored Pfizer deal: ‘It’s all noise, until it isn’t’

by

Pfizer is the latest company rumored to be buying antibody-drug conjugate (ADC) developer Seagen, but Seagen says the deal is all noise… until it isn’t.   The potential acquisition of Seagen (previously Seattle Genetics) has been circulating news outlets since June last year when the Wall Street Journal reported Merck & Co. was interested in buying the Bothell, Washington to increase its oncology portfolio and pipeline. Last week, the same outlet reported Pfizer is considering purchasing the ADC manufacturer.   While the deal is speculative…

March 3, 2023

Unbiased nature of TEM ideal complement to in-vitro assays

by

Transmission Electron Microscopy (TEM) is the ideal complement to in-vitro assays and molecular techniques in determining the microbiological safety of biological products. TEM is a powerful tool in the biopharmaceutical industry, allowing for high resolution imaging of microscopic structures at the nanometer scale. This technique utilizes a beam of electrons that passes through a thin section of a specimen, producing detailed images of the internal structure of the sample. With the ability to magnify samples up to one million times…

March 3, 2023